TISIDB

Summary
Symbol	EPHA1
Name	EPH receptor A1
Aliases	EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location	7q32-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein
Domain	PF14575 Ephrin type-A receptor 2 transmembrane domain PF01404 Ephrin receptor ligand binding domain PF00041 Fibronectin type III domain PF07714 Protein tyrosine kinase PF00536 SAM domain (Sterile alpha motif)
Function	Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Binds with a low affinity EFNA3 and EFNA4 and with a high affinity to EFNA1 which most probably constitutes its cognate/functional ligand. Upon activation by EFNA1 induces cell attachment to the extracellular matrix inhibiting cell spreading and motility through regulation of ILK and downstream RHOA and RAC. Plays also a role in angiogenesis and regulates cell proliferation. May play a role in apoptosis.

> Gene Ontology [ TOP ]
Biological Process	GO:0001525 angiogenesis GO:0001933 negative regulation of protein phosphorylation GO:0001952 regulation of cell-matrix adhesion GO:0001954 positive regulation of cell-matrix adhesion GO:0006469 negative regulation of protein kinase activity GO:0007015 actin filament organization GO:0007160 cell-matrix adhesion GO:0010810 regulation of cell-substrate adhesion GO:0010811 positive regulation of cell-substrate adhesion GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0019827 stem cell population maintenance GO:0030038 contractile actin filament bundle assembly GO:0030335 positive regulation of cell migration GO:0030336 negative regulation of cell migration GO:0031032 actomyosin structure organization GO:0031589 cell-substrate adhesion GO:0032231 regulation of actin filament bundle assembly GO:0032233 positive regulation of actin filament bundle assembly GO:0032956 regulation of actin cytoskeleton organization GO:0032970 regulation of actin filament-based process GO:0033673 negative regulation of kinase activity GO:0034446 substrate adhesion-dependent cell spreading GO:0035019 somatic stem cell population maintenance GO:0040013 negative regulation of locomotion GO:0040017 positive regulation of locomotion GO:0042326 negative regulation of phosphorylation GO:0043149 stress fiber assembly GO:0044089 positive regulation of cellular component biogenesis GO:0045765 regulation of angiogenesis GO:0045766 positive regulation of angiogenesis GO:0045785 positive regulation of cell adhesion GO:0046777 protein autophosphorylation GO:0048013 ephrin receptor signaling pathway GO:0048514 blood vessel morphogenesis GO:0051017 actin filament bundle assembly GO:0051271 negative regulation of cellular component movement GO:0051272 positive regulation of cellular component movement GO:0051348 negative regulation of transferase activity GO:0051492 regulation of stress fiber assembly GO:0051493 regulation of cytoskeleton organization GO:0051495 positive regulation of cytoskeleton organization GO:0051496 positive regulation of stress fiber assembly GO:0061572 actin filament bundle organization GO:0090630 activation of GTPase activity GO:0098727 maintenance of cell number GO:1901342 regulation of vasculature development GO:1904018 positive regulation of vasculature development GO:2000146 negative regulation of cell motility GO:2000147 positive regulation of cell motility
Molecular Function	GO:0004713 protein tyrosine kinase activity GO:0004714 transmembrane receptor protein tyrosine kinase activity GO:0005003 ephrin receptor activity GO:0005005 transmembrane-ephrin receptor activity GO:0019199 transmembrane receptor protein kinase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04360 Axon guidance
Reactome	R-HSA-422475: Axon guidance R-HSA-1266738: Developmental Biology R-HSA-2682334: EPH-Ephrin signaling R-HSA-3928665: EPH-ephrin mediated repulsion of cells R-HSA-3928663: EPHA-mediated growth cone collapse R-HSA-2892247: POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation R-HSA-452723: Transcriptional regulation of pluripotent stem cells

Summary
Symbol	EPHA1
Name	EPH receptor A1
Aliases	EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location	7q32-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between EPHA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	EPHA1
Name	EPH receptor A1
Aliases	EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location	7q32-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of EPHA1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	EPHA1
Name	EPH receptor A1
Aliases	EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location	7q32-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of EPHA1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.51	0.232
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.084	0.903
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.958	0.115
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.124	0.776
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.206	0.925
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.54	0.844
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.682	0.406
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.074	0.367
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.15	0.904
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.606	0.0409
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.813	0.1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.143	0.348

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of EPHA1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	0	14.8	0.00448
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	0	14.8	0.00826
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	0	7.9	0.26
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	EPHA1
Name	EPH receptor A1
Aliases	EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location	7q32-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EPHA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	EPHA1
Name	EPH receptor A1
Aliases	EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location	7q32-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EPHA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EPHA1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	EPHA1
Name	EPH receptor A1
Aliases	EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location	7q32-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EPHA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	EPHA1
Name	EPH receptor A1
Aliases	EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location	7q32-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of EPHA1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	EPHA1
Name	EPH receptor A1
Aliases	EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location	7q32-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between EPHA1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	EPHA1
Name	EPH receptor A1
Aliases	EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location	7q32-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting EPHA1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse EPHA1